Exicure to Participate in Upcoming Investor Conferences
September 01 2021 - 7:00AM
Business Wire
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced participation in the following investor
conferences during the month of September:
Citi’s 16th Annual Biopharma Conference 2021 One-on-one
meetings September 8-10, 2021
H.C. Wainwright 23rd Annual Global Investment Conference
Presentation Time: 7:00 AM ET Virtual webcast here Monday,
September 13, 2021
Baird Global Healthcare Conference Presentation Time:
9:40 AM ET Tuesday, September 14, 2021
Replays of the H.C. Wainwright webcast will be available on
Exicure’s website for 30 days following the event.
About Exicure, Inc. Exicure, Inc. is a clinical-stage
biotechnology company developing therapeutics for neurology,
immuno-oncology, inflammatory diseases and other genetic disorders
based on its proprietary Spherical Nucleic Acid, or SNA technology.
Exicure believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN a
lipid-nanoparticle SNA–based therapeutic candidate, for the
intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s
therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2
clinical trial in patients with advanced solid tumors. Exicure is
based in Chicago, IL and in Cambridge, MA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210901005158/en/
Media Contact: Karen Sharma MacDougall 781-235-3060
ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024